Search Results - Hof, Arjan C. van

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: A phase I study

    Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: A phase I study by Moltoff, Carla F.M., Prinssen, Helma M., Kenemans, Peter, Hof, Arjan C. van, Hollander, Wim den, Verheijen, René H.M.

    Published in Cancer
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  2. 2
    Biodistribution of (111)indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose

    Biodistribution of (111)indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose by van Hof, A C, Molthoff, C F, Davies, Q, Perkins, A C, Verheijen, R H, Kenemans, P, den Hollander, W, Wilhelm, A J, Baker, T S, Sopwith, M, Frier, M, Symonds, E M, Roos, J C

    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Biodistribution of 111 In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01

    Biodistribution of 111 In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01 by Prinssen, Helma M., Molthoff, Carla F. M., Verheijen, René H. M., Broadhead, Tim J., Kenemans, Peter, Roos, Jan C., Davies, Quentin, van Hof, Arjan C., Frier, Malcolm, den Hollander, Wim, Wilhelm, Abraham J., Baker, Terry S., Sopwith, Mark, Symonds, E. Malcolm, Perkins, Alan C.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Biodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients : influence of prior administration of unlabelled hCTM01

    Biodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients : influence of prior administration of unlabelled hCTM01 by PRINSSEN, H. M, MOLTHOFF, C. F. M, WILHELM, A. J, BAKER, T. S, SOPWITH, M, SYMONDS, E. M, PERKINS, A. C, VERHEIJEN, R. H. M, BROADHEAD, T. J, KENEMANS, P, ROOS, J. C, DAVIES, Q, VAN HOF, A. C, FRIER, M, DEN HOLLANDER, W

    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOV18 : I.V. vs. I.P

    Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOV18 : I.V. vs. I.P by VAN ZANTEN-PRZYBYSZ, Iwona, MOLTHOFF, Carla F, ROOS, Jan C, VERHEUEN, René H, VAN HOF, Arjan, BUIST, Marrije R, PRINSSEN, Helma M, DEN HOLLANDER, Wim, KENEMANS, Peter

    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p

    Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p by van Zanten‐Przybysz, Iwona, Molthoff, Carla F., Roos, Jan C., Verheijen, René H., van Hof, Arjan, Buist, Marrije R., Prinssen, Helma M., den Hollander, Wim, Kenemans, Peter

    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v.vs. i.p

    Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v.vs. i.p by van Zanten-Przybysz, Iwona, Molthoff, Carla F., Roos, Jan C., Verheijen, René H., van Hof, Arjan, Buist, Marrije R., Prinssen, Helma M., den Hollander, Wim, Kenemans, Peter

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:

Search Tools: